



Different Types of Therapies in Corneal Regeneration

Sanjana and Ankit Thakur*

Department of Pharmacy Practice, Samskruti College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, India

***Corresponding Author:** Ankit Thakur, Department of Pharmacy Practice, Samskruti college of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, India.

Received: December 22, 2023

Published: January 18, 2024

© All rights are reserved by **Sanjana and Ankit Thakur**.

Abstract

The ocular surface is the outermost part of the visual system can experience physical or chemical damage from external or internal factors such as thermal harm, infectious pathogens, and burns, Steven Johnson Syndrome or, other autoimmune diseases. Limbal cells possess stem cell qualities and regenerative capabilities due to their capacity for differentiation. The regeneration of corneal wounds involves a multifaceted process encompassing cell death, proliferation, migration, differentiation, and remodeling of the extracellular matrix. Among various therapies for corneal regeneration, stem cell therapy stands out as the most promising due to its rapid recovery from infections. Although still in its early stages, interventions for treating corneal abnormalities are underway. These interventions involve the use of both viral and non-viral vectors to introduce genes into the cornea, employing in vivo, ex vivo, and in vitro methods. This review primarily focuses on the latest advancements utilizing biological modulators like gene therapy, signaling inhibitors, microRNA, and Nano formulations. Additionally, the paper concentrates on the latest therapies utilizing stem cells and advancements in the ocular drug delivery system, aiming to enhance potential therapies for the future treatment of ocular diseases.

Keywords: Stem Cells; Rock Inhibitor; Gene Therapy; Corneal Regeneration; Micro RNA; and Corneal Damage

Introduction

Due to its position as the eye's outermost layer, the cornea is subject to various environmental strains, including burns, infections, abrasions, and conditions like refractive surgeries, which prompt tissue healing processes. Cornea comprises of 3 types of cells: -the stratified surface epithelium, the stromal keratocytes, and innermost single layer endothelium cells. Following the closure of the defect, the epithelial cells undergo migration, proliferation, and differentiation. These are also accompanied by apoptosis. These keratocytes are replaced by live cells without scarring [1]. Corneal transplantation is done generally but the individual receive LASIK surgeries also contribute 2% complication with abnormal wound healing. Corneal endothelium unlike other cells repair by cell migration and spreading. Particular attention is placed on the most recent techniques involving biological regulators such as gene therapy, inhibitors of signaling, micro RNA, and Nano formulations [2]. The healing of corneal wounds involves a complicated sequence of events: cells experience death, multiply, migrate,

differentiate, and remodel the extracellular matrix. The renewal of the epithelial layer holds significance as it creates a protective barrier, safeguarding the inner cornea from harmful environmental elements [3].

Pathogenesis of corneal damage

Corneal damage refers to an injury within the eye's transparent covering, called the cornea, which aids in visualizing objects [4]. About 3% of emergency visits are due to corneal damage. These corneal damages may be mild to moderate and sometimes may also cause vision-threatening. Corneal injuries can be broadly divided into two categories one is traumatic (corneal abrasions and foreign exposure) and second is exposure (burns due to chemical, thermal, radiation) [5]. Damage to the cornea is linked to various conditions, including genetic or degenerative disorders such as conjunctivitis, dry eye, keratoconus, pterygium, cataracts, as well as certain infectious agents [6]. All the agents cause corneal damage in the following pathway.

The corneal epithelium is the softest and smooth part that lacks vascularization and derives nutrients from tear fluid [7]. The extent of burns and infections is determined by how long and intense the damaging agents affect the area. When cornea gets exposed to strong alkaline chemicals it causes liquefactive necrosis of cells while acid burns cause coagulation necrosis [5]. Liquefactive necrosis, involving degenerative neutrophils, causes irreversible damage and is considered more hazardous compared to coagulation necrosis, which arises from protein denaturation [8].

There are three stages in pathogenesis of corneal damage that include.

Corneal infection

The most common agents include bacteria, fungus, protozoa, and parasites. Upon entry, these microorganisms reduce the concentration of host defense systems, primarily affecting the tear film and certain enzymes like lysozyme, lactoferrin, and phospholipase A2, defensins, statins, and cathelicidins which leads to a condition known as microbial keratitis.

Corneal fibrosis

This leads to a loss of transparency of the cornea. Under typical circumstances, the corneal epithelium can replenish its cells within 3-4 days of infection through the migration of healthy epithelial cells to the affected area. However, when the injury penetrates deeply into the stroma, cell regeneration becomes difficult, resulting in significant vision impairment [9]. Epithelial stromal injury in the cornea is a starting process in the development of myofibroblasts. Myofibroblasts, derived either from keratocyte or bone marrow precursors, significantly contribute to stromal opacity. Research indicates that TGF-β enhances the maturation of myofibroblasts and inhibits IL-1 induced apoptosis in mature myofibroblasts, leading to a loss of corneal transparency [10].

Corneal neovascularisation

This condition poses a threat and is instigated by various agents, driven by angiogenic factors like IL-8. If left unaddressed, approximately 1.4 million individuals annually may experience edema, lipid accumulation, and ongoing inflammation. Mainly Herpes simplex keratitis leads in developing this condition mediated by vascular endothelial growth factor (VEGF). The process of an-

giogenesis involves an elevated release of VEGF caused by the suppression of VEGF receptor synthesis (sVEGFR-1), resulting in the formation of delicate blood vessels within the cornea. IL-6 and IL-7 also stimulate the production of VEGF. This harms light diffraction mechanisms and leads to blindness when untreated [11].

Gene therapy

This therapy involves employing genes rather than drugs or surgical procedures to treat the disease. Gene therapy either substitutes the faulty gene causing the condition with a healthy one, deactivates the mutated gene, or introduces a new gene to assist in combating the disease, offering potential treatments for patients [12]. In ophthalmology, the cornea's transparency and lack of blood vessels make it an optimal tissue for gene therapy, facilitating easier treatment. Despite being at an early stage, interventions for addressing corneal abnormalities are underway. This involves the utilization of various viral and non-viral vectors to introduce genes into the cornea through *in vivo*, *ex vivo*, and *in vitro* methods. The list of vectors is mentioned below in table 1.

Viral vectors	Non-viral vectors
Adeno and adeno-associated virus	Plasmid DNA
Retrovirus	Lipids
Lentivirus	Polymers
	Nanoparticles.

Table 1: Types of viral and non-viral vectors.

This therapy utilizes methods such as gene gun application, electroporation, intrastromal injection, and iontophoresis to introduce genes, whether through viral or non-viral vectors [13].

Rock inhibitors

Rho kinase (ROCKs) are effectors in the Rho pathway which are serine/tyrosine kinases. The primary function of ROCKs is associated with cell growth, movement, and the reorganization of the actin cytoskeleton, ultimately resulting in tissue cell death. These ROCKs are expressed in the cornea, involve in corneal healing and cell differentiation. So, the use of ROCK inhibitors will improve corneal wound healing. Corneal endothelial cells (CEC) are the sites of ROCK expression. These cells play a main role in corneal transparency. The utilization of ROCK inhibitors induces the inactivity

of these cells, aiding in the facilitation of endothelial regeneration processes¹.

The main use of ROCK inhibitors can be seen in several conditions where the outcome is increased retinal blood flow and improved vision. The list of diseases where ROCK inhibitors are used are listed below along with outcome:

- Fuchs endothelial corneal dystrophy (FECD) - preserving corneal clarity
- Failure of central Descemetorhexis - salvage treatment
- Glaucoma - increased intraocular pressure (IOP)
- Diabetic retinopathy - vasodilation in the retina (optic nerve head) [14].

Examples

Ripasudil.

It is used in glaucoma treatment with chemical formula C₁₅H₁₈FN₃O₂S known as fluoro-5(((2S)-2-methyl-1, 4-diazepam-1-yl) sulfonyl) isoquinoline. It is available in the form of drops and onset of action within 2 hours. The common side effect is conjunctival hyperaemia.

Netarsudil

The compound with the chemical formula C₂₈H₂₇N₃O₃, recognized as (4-((1S)-1-(Aminomethyl)-2-(isoquinoline-6-aryl amino)-2-oxoethyl) phenyl) methyl 2, 4-dimethylbenzoate, combines ROCK inhibitory properties with norepinephrine transport inhibition. It is also the same onset of action i.e. 2 hours after installation of drops and similar side effects as that of ripasudil [15].

Micro RNAs

microRNAs (miRNAs) are small, non-coding RNA molecules found in multicellular eukaryotic organisms that are important in regulating translational repression of cells [16]. These bind with target mRNAs at 3'-untranslated region for regulating post-transcriptional gene expression. Approximately a quarter (25%) of miRNAs are situated in the eye's corner and oversee various

aspects of corneal functionality, such as development, differentiation, glycogen metabolism, post-injury regeneration, and the maintenance of corneal epithelial progenitor cell (CEPC) balance. In pathological circumstances, these miRNAs also govern conditions like keratoconus and corneal neovascularization resulting from events like corneal transplantation, herpes simplex virus infection, and alkali burns. Consequently, mRNAs have emerged as promising therapeutic targets for treating corneal diseases [17]. miR-143 and 145, as well as miR-10b, 126, and 155, are situated within the basal layers of the limbal epithelium [18].

Amidst the migration and proliferation of corneal epithelial cells, miR-205 plays a pivotal role in promoting corneal healing. It achieves this by targeting SH2-containing phosphoinositide-5-phosphatase (SHIP2), consequently influencing the Akt signaling pathway essential for cell migration and enhancing motility by altering F-actin organization. Additionally, miR-205 suppresses the KCNJ10 channel gene, thereby encouraging epithelial cell proliferation. Therapeutically, this approach involves augmenting natural miRNAs, mimicking their natural functions, or employing antagomirs to inhibit their overexpression [19].

Nano formulation

In Nano medicine, it includes medical application of nanotechnology, Nano devices (contact lens) and nanoparticles (silicate, gold, silver, platinum, calcium phosphate, etc.), nanomaterial (nanofibers), nano delivery (liposome, dendrimers, polymeric micelles, nano emulsion) in tissue repair and drug delivery for corneal treatment. Nanomedicine in corneal regeneration primarily centers on utilizing materials ranging from 10 to 100 nanometers in size. Its focus includes imaging, as well as the prevention or reduction of corneal opacity and neovascularization.

Nanoparticles utilized encompass various types such as platinum nanoparticles known for their anti-aging properties. Polymeric nanoparticles, composed of polyethyleneimine, albumin, chitosan, and polyethylene glycol, are employed to deliver transgenes to corneal endothelial cells in laboratory settings. Additionally,

¹TGF beta: -Transforming Growth Factor beta; IL-1:- Interleukin 1; VEGF:-Vascular Endothelial Growth Factor; VEGFR 1:- Vascular Endothelial Growth Factor Receptor; CEC:- Corneal Endothelial cells

metallic nanoparticles coupled with polymeric ones, like 2kDa PEI with PEI2-Au-NPs, aid in gene delivery to the cornea in laboratory setups. Meanwhile, non-metallic nanoparticles such as CaP-NPs (calcium phosphate nanoparticles) are both biocompatible and biodegradable. When integrated into the eye, they break down into calcium and phosphate within corneal endothelial cells, facilitating cellular transparency restoration. Nanofibers are used in corneal regeneration when the scaffold-like tissue bridging nanostructures that contain peptides. Upon integration into the cornea, the scaffold's structure offers a framework that facilitates cell adhesion and migration, thereby enhancing corneal repair. Additionally, a combination of octopamine dendrimers cross-linked with collagen using polypropylene imine supports corneal cell growth and adhesion. Nano devices find primary application in providing prolonged drug release during ocular surgeries. For instance, nanospheres composed of pullulan and polycaprolactone, coated with ciprofloxacin, are utilized primarily for treating infections caused by *Staphylococcus aureus* and *Pseudomonas aeruginosa* in the eye [20].

Different therapies of corneal regeneration

With corneal epithelium

The slow healing of corneal epithelium cells in vivo is due to the preservation of their ability to proliferate and the reduction of DNA replication errors. This process unfolds in three distinct ways: -

- The usual attachment of hemi-desmosomes to the epithelial matrix and other anchoring structures is disrupted, leading to the formation of a temporary structure termed focal contacts. The epithelial cells get flattened and migrate as a sheet and independent of cellular proliferation.
- The cell stratification and differentiation take place.
- Finally, the hemi-desmosomes are reconstructed, and the synthesis of extracellular matrix occurs.

This wound healing process is brought about by complex cascade events including cytokine-mediated interactions between the epithelial cells keratocytes of the corneal stroma, corneal nerve, lacrimal glands, and cells of the Immune system. The level of the interaction is dependent on the inciting injury [21].

Extraction of CCG

Compressed collagen hydrogels were made using the RAFT Reagents. In short, acid-soluble rat-tail collagen was neutralized and diluted to a concentration of 1.6 mg/ml in a solution consisting of 1 × Minimal Essential Medium. This collagen solution, typically 1 ml, was placed into wells of a 24-well culture dish containing 12 mm round glass coverslips. The collagen was solidified in a 37°C CO₂ incubator for 1 hour, followed by dehydration for 15 minutes at room temperature using fibrous absorbers in a laminar flow hood. Afterward, the collagen gels were moved to a 60 mm petri dish in sterile phosphate-buffered saline (PBS). Using a sterile disposable biopsy punch with a plunger, 2 mm diameter disks were punched out for further analysis. Collagen gels without cells were stored in sterile PBS, while those with cells were kept in stem cell growth medium at 37°C in a CO₂ incubator for up to 2 weeks. Some gels without cells were stained with Daylight 633 dye before sectioning, rinsed with 0.1 M NaHCO₃, and then stained with Daylight 633 NHS Ester reactive dye (0.25 mg/ml in 0.1 M NaHCO₃, pH 8.5) for 2 hours at room temperature. Following staining, the CCGs were washed in sterile PBS and stored at 4°C until use [25].

Placement of CCG on cornea

This led to a strong attachment of the compacted collagen to the eye's surface [26]. This approach offers a quick and practical way to inhibit scarring and facilitate the regeneration of corneal tissue. It proves advantageous for individuals experiencing corneal scarring without any other available treatment options [27].

With umbilical cord

The corneal endothelium consists of a monolayer of cells derived from the neural crest and mesoderm. Its primary role is to inhibit the development of corneal edema by regulating the function of zonular occludens-1 (ZO-1) and the Na, K- ATPase pump [28]. The Human umbilical cord is a rich source of mesenchymal cells that acts as an allogenic source [29].

Upon initiating differentiation using a medium containing glycogen synthase kinase (GSK)-3-beta inhibitors, UC-MSCs exhibited a transformation into polygonal structured cells. Validation of the presence of significant corneal markers was conducted using reverse transcription-polymerase chain reaction (RT-PCR) and

quantitative RT-PCR (qRT-PCR). Western blotting was employed to verify the expression of Na-K ATPase and PITX2 [30].

The Localization of Na-K ATPase and ZO-1 occurs in cell junction which indicates the presence of tight junction. So UTECE may be used as an important source of allogeneic cells for the treatment of corneal disease [31].

The cornea plays a very important role in conducting light into the eyes and protecting intraocular structures. With the impairment of cornea these functions get affected that lead to affecting the internal structures. So it's very important to maintain corneal health. From the above mentioned procedures the damage of the cornea can be repaired to most of the extent.

Future hopes

A phase 2 interventional study, which is open-label and single-centered, commenced on February 9, 2015. Its objective is to assess the safety and viability of utilizing cultivated autologous limbal epithelial cells transplantation to treat limbal stem cell deficiency in approximately 17 patients. The interventional approach involves utilizing cultivated autologous limbal epithelial cell therapy, employing a bio-engineered combination of ex-vivo expanded autologous corneal epithelial cells. Additionally, FDA-approved materials such as an amniotic membrane-like amino graft and Bio-Tissue are utilized for reconstructing the ocular surface. A biopsy of 2 to 3 mm is taken as a source of epithelial cells, which are then expanded on the amniotic membrane in culture and subsequently transplanted onto the cornea after removal of fibro vascular pannus.

In contrast, the study arm procedure entails obtaining a corneal biopsy from the non-diseased eye to acquire cells for the CALEAC graft. Both arms are monitored over a 2-year period to assess safety outcomes, including occurrences of ocular infection, perforation, graft detachment, adverse effects, and the feasibility of achieving cell growth, maintaining cell viability, and preventing culture contamination throughout the 2-year duration [32].

In a randomized, quadruple masked trial focusing on corneal dystrophy including epithelial basement membrane dystrophy and recurrent erosion dystrophy, alongside corneal erosions, the efficacy of CACICOL20® (RGTA OTR 4120) is being investigated.

The study aims to assess its effectiveness in enhancing wound healing and nerve regeneration in the anterior cornea among approximately 40 subjects. After undergoing therapeutic laser treatment of the cornea at a single clinic, participants receive either the treatment or a placebo in the form of three eye drops in total, with the first dose administered two days after surgery and the final dose four days post-surgery. Postoperative eye examinations for measurement of various eye and corneal wound healing parameters are conducted on days 2 and 7 at months 6 and 12. The interventional arm includes an investigational device, regenerating agent, single-use doses, and topical eye drops that are indicated for corneal wound healing and other group using a placebo with identical packaging and include dosage and administration route. The experimental group includes Cacicol 20eye drops after laser corneal surgery. A total of three eye drops are to be administered immediately following the surgical procedure. The main assessment measures the percentage of recovery in sub-basal nerve density over a period of 12 months [33].

A combined phase 1/phase 2 study is assessing the safety and effectiveness of an investigational new drug, TTHX1114 (NM141), aimed at regenerating corneal endothelial cells in patients with corneal endothelial dystrophies through intracameral delivery. This study involves multiple centers and is randomized, masked, vehicle-controlled, and includes a dose-escalation design. It incorporates an observational sub-study with 25-50 subjects.

The interventional arms consist of TTHX1114 (NM141), an engineered FGF-1 drug, delivered intracamerally, while other groups receive a placebo. The study arm comprises the following: a placebo comparator vehicle administered weekly for 4 weeks; an experimental group receiving a low dose of TTHX1114 (NM141) weekly for 4 weeks; a mid-dose group receiving TTHX1114 (NM141) weekly for 4 weeks; and another group receiving a high dose of TTHX1114 (NM141) weekly for 4 weeks. The primary outcome measure assesses changes in corneal endothelial cell count over a period of 56 days [34].

Conclusion

The cornea, highly sensitive and prone to infections and injuries, is the primary focus of stem cell therapy. This approach involves using adult autologous stem cells derived from an individual's bone marrow or adipose tissue to facilitate healing and regeneration of

damaged eye tissue. Stem cell therapy eliminates the need for donors or associated complexities. However, ongoing research aims to enhance treatment strategies and eye transplant techniques. It's important to note that not everyone may benefit from stem cell treatments, especially in cases of severe corneal damage. Effective treatment often relies on the presence of undamaged limbal stem cells in one eye that can be extracted and injected into the damaged eye. Additionally, stem cell therapy becomes more challenging in cases where patients suffer from infections affecting both corneas.

Acknowledgement

We thank anonymous referees for their usual suggestions.

Conflict of Interest

None.

Ethical Statement not Required

Not required

Funding Statement

Not applicable.

Bibliography

1. Saghizadeh M., *et al.* "Concise Review: Stem Cells for Corneal Wound Healing". *Stem Cells* 35.10 (2017): 2105-2114.
2. Ljubimov A V and Saghizadeh M. "Progress in corneal wound healing". *Progress in Retinal and Eye Research. Elsevier Ltd* 49 (2015): 17-45.
3. Klyce SD. "Electrical profiles in the corneal epithelium". *Journal of Physiology* 226.2 (1972): 407-429.
4. Corneal injury: MedlinePlus Medical Encyclopedia (2020).
5. Cornea Injury - an overview | ScienceDirect Topics (2020).
6. Cornea Fort Worth | External Diseases | Ophthalmology Associates (2020).
7. Corneal Anatomy (2020).
8. Hanna P. "Cellular Pathology (VPM 152) Lecture 4". Yahoo India Search Results (2020).
9. Chaurasia SS., *et al.* "Nanomedicine Approaches for Corneal Diseases". *Journal of Functional Biomaterials* 6 (2015): 277-298.
10. Torricelli AAM., *et al.* "The corneal fibrosis response to epithelial-Stromal injury". *Experimental Eye Research. Academic Press* (2016): 110-118.
11. Sharif Z and Sharif W. "Corneal neovascularization: updates on pathophysiology, investigations and management". *Romanian Journal of Ophthalmology* 63.1 (2019): 15-22.
12. What is gene therapy? - Genetics Home Reference - NIH (2020).
13. Mohan RR., *et al.* "Gene therapy in the Cornea: 2005-present". *Progress in Retinal and Eye Research. NIH Public Access* 31 (2012): 43-64.
14. Rho kinase inhibitors – EyeWiki (2020).
15. Moshirfar M., *et al.* "Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature". *Medical Hypothesis, Discovery and Innovation in Ophthalmology* 7.3 (2018): 101-111.
16. Wang Y., *et al.* "MicroRNA-182 mediates sirt1-induced diabetic corneal nerve regeneration". *Diabetes* 65.7 (2016): 2020-2031.
17. "Expression and function of microRNAs in the cornea" (2020).
18. Teng Y., *et al.* "Signature microRNAs in human cornea limbal epithelium". *Functional and Integrative Genomics* 15.3 (2015): 277-294.
19. Ljubimov A V and Saghizadeh M. "Progress in corneal wound healing". *Progress in Retinal and Eye Research. Elsevier Ltd* 49 (2015): 17-45.
20. Chaurasia S., *et al.* "Nanomedicine Approaches for Corneal Diseases". *Journal of Functional Biomaterials* 6.2 (2015): 277-298.
21. Agrawal VB and Tsai RJF. "Corneal epithelial wound healing". *Indian Journal of Ophthalmology. Medknow Publications and Media Pvt. Ltd* 51 (2003): 5-15.
22. Shojaati G., *et al.* "Compressed Collagen Enhances Stem Cell Therapy for Corneal Scarring". *STEM CELLS Translational Medicine* 7.6 (2018): 487-494.

23. Hu K., *et al.* "Compressed collagen gel as the scaffold for skin engineering". *Biomed Microdevices* 12.4 (2010): 627-635.
24. Vaissiere G., *et al.* "Comparative analysis of different collagen-based biomaterials as scaffolds for long-term culture of human fibroblasts". In: *Medical and Biological Engineering and Computing*. Peter Peregrinus Ltd (2000): 205-210.
25. Auger FA., *et al.* "Tissue-engineered skin substitutes: from in vitro constructs to in vivo applications". *Biotechnology and Applied Biochemistry* 39.3 (2004): 263-275.
26. Lee CH., *et al.* "Biomedical applications of collagen". *International Journal of Pharmaceutics* 221.1-2 (2001): 1-22.
27. Jones I., *et al.* "A guide to biological skin substitutes". *British Journal of Plastic Surgery*. Churchill Livingstone 55 (2002): 185-193.
28. Ophthalmology Ziaei M., *et al.* "Umbilical Cord Stem Cells in the Treatment of Corneal Disease". *Survey on Ophthalmology* (2017).
29. Coulson-Thomas VJ., *et al.* "Transplantation of human umbilical mesenchymal stem cells cures the corneal defects of mucopolysaccharidosis VII mice". *Stem Cells* 31.10 (2013): 2116-2126.
30. Chen Y., *et al.* "Identification of novel molecular markers through transcriptomic analysis in human fetal and adult corneal endothelial cells". *Human Molecular Genetics* 22.7 (2013): 1271-1279.
31. Chang YJ., *et al.* "Characterization of two populations of mesenchymal progenitor cells in umbilical cord blood". *Cell Biology International* 30.6 (2006): 495-499.
32. Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft - Full Text View - ClinicalTrials.gov (2020).
33. Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy - Full Text View - ClinicalTrials.gov (2020).
34. A Phase 1/ Phase 2 Study of TTHX1114 (NM141) - Full Text View - ClinicalTrials.gov (2020).